Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of Presendin in active idiopathic intracranial hypertension
MOH_2023-04-18_012546Phase 3Completed
- Sponsor
- Invex Therapeutics Ltd
- Start
- Mar 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic intracranial hypertension (IIH) comparing Presendin with Placebo (2 arms). Primary endpoint: Change in intracranial pressure. Started Mar 2023; status: completed.
02
Drugs
Presendin
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on MOH_2023-04-18_012546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-18_012546.